# Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis

> **NCT01480076** · PHASE4 · COMPLETED · sponsor: **Biogen** · enrollment: 901 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Fampridine

## Key facts

- **NCT ID:** NCT01480076
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2013-07
- **Final completion:** 2013-08
- **Target enrollment:** 901 (ACTUAL)
- **Last updated:** 2017-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01480076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01480076, "Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01480076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*